Bayer Schering/Sonus’ Tocosol Paclitaxel Fails Phase III Pivotal Breast Cancer Trial

Tocosol paclitaxel Phase III trial fails to meet primary endpoint on noninferiority compared to Taxol control arm; trials discontinued, agreement with Bayer Schering could end, Sonus announces.